Skip to content

KY-19382

Also called KY19382; 5,6-dichloroindirubin-3'-methoxime — an indirubin-3'-monoxime (I3O) analog that activates Wnt/beta-catenin signaling by blocking the CXXC5–Dishevelled interaction. From Kang-Yell Choi's group; sibling molecule KY19334 comes from the same program and is NOT the same compound

A brake release, not an accelerator.

  • TypeSmall molecule
  • FormTopical
  • Researched forHealing & Recovery

Where to get KY-19382

Disguised Alpha
Topical
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop topical at Disguised Alpha

The short version

  • Why people research itA Wnt/beta-catenin pathway activator acting through blockade of the CXXC5–Dishevelled interaction, studied for hair regrowth and hair follicle neogenesis, cutaneous wound healing, and dermal matrix and collagen…
  • What the evidence isNo human trial of KY-19382 exists, and no pharmacokinetic study in any species.
  • What to watchA mole or patch that changes after weeks of use.

How KY-19382 works

A brake release, not an accelerator — which is the whole argument for it. CXXC5 is a negative-feedback regulator of Wnt/beta-catenin signaling: in the cytosol it binds Dishevelled (Dvl) and blocks Dvl's job inside the Wnt signalosome, so the pathway stays damped. KY-19382 is a small molecule that inhibits that CXXC5–Dvl protein-protein interaction. Freed Dvl restores signalosome function, GSK-3beta-mediated phosphorylation of beta-catenin falls, beta-catenin escapes beta-TrCP-dependent ubiquitination and proteasomal degradation, accumulates, enters the nucleus and partners with TCF/LEF to transcribe Wnt target genes. In hair that matters because dermal papilla Wnt/beta-catenin activity is what drives anagen: in human dermal papilla cells KY-19382 raised beta-catenin, alkaline phosphatase and the proliferation marker PCNA. Chemically it is 5,6-dichloroindirubin-3'-methoxime, an analog of indirubin-3'-monoxime. CXXC5 is also the node through which DHT suppresses follicles via PGD2, which places this mechanism directly downstream of the androgen problem rather than beside it.

The important thing about this molecule is the kind of intervention it is, not the pathway it touches. Every compound that raises Wnt/beta-catenin signaling invites the same objection — that Wnt drives proliferation and proliferation drives tumors — and the answer depends entirely on where in the pathway you push.

The target, named precisely. CXXC5 — CXXC-type zinc finger protein 5 — is a negative regulator of Wnt/beta-catenin signaling Ryu 2023. Its relevant activity is cytosolic rather than nuclear: it binds Dishevelled (Dvl) and occupies the interaction surface Dvl needs in order to function inside the Wnt signalosome at the membrane.

  • Topical

On the goal map: Hair — follicle biology & the androgen problem (Skin, hair & aesthetics)

Research on KY-193829 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Theoretical — mouse in vivo plus human cell and human hair follicle organ culture (Kang-Yell Choi's group, Yonsei). Multiple independent mouse models and ex vivo human follicles; no human trial of KY-19382 exists.

Human clinical evidence

  • No human trial of KY-19382 exists, and no pharmacokinetic study in any species. The molecule has a substantial preclinical record and zero human exposures in the published literature.

    No completed human trial
  • The closest thing to human data is human tissue, not a human. KY-19382 increased hair length in cultured human hair follicles and raised beta-catenin, alkaline phosphatase and PCNA in human dermal papilla cells (Ryu 2021); it drove migration of human keratinocytes and dermal fibroblasts with increased Collagen I, Keratin 14, PCNA and alpha-smooth muscle actin (Yoon 2023); and it restored the length of human hair follicles shortened under high-glucose culture (Ryu 2022). Explanted follicles and cultured cells are a genuinely stronger starting point than rodent-only data, and they are still not a person. This tier stays empty on purpose.

Correlative data

  • No human association, observational or uncontrolled data on KY-19382 either. What does exist at the human level is target validation rather than compound evidence: CXXC5 is overexpressed, with Wnt/beta-catenin signaling and its wound-healing and angiogenesis target genes suppressed, in wound tissue from diabetic foot ulcer patients (Kim 2023), and CDK1 induction with Wnt/beta-catenin activation was found in human cutaneous squamous cell carcinoma samples against normal samples (Lee 2025). So the pathway this molecule acts on is demonstrably dysregulated in human skin disease in both directions. That is a reason the target is real. It is not evidence about the bottle.

How the mechanism reads

  • The mechanism is a protein-protein interaction block, which is why it reads as restorative rather than driving. CXXC5 is a negative regulator of Wnt/beta-catenin that works by binding Dishevelled; KY-19382 was identified as a Wnt/beta-catenin activator via inhibition of the CXXC5–Dvl interaction (Ryu 2021). Lifting a brake has a ceiling set by how much upstream Wnt tone the tissue actually has. That distinction carries most of the weight in this page's safety section.

    Mechanistic
  • Three separate in vivo hair models, which is more than most compounds here manage. In C57BL/6 mice KY-19382 induced hair regrowth, and promoted generation of de novo hair follicles as shown by wound-induced hair follicle neogenesis (WIHN) and hair patch assays (Ryu 2021). Follicle neogenesis is a different and more demanding claim than lengthening existing hairs, and it is the one that makes this mechanism interesting rather than incremental.

    Experimental, animal or cell
  • It puts the mechanism downstream of the androgen problem instead of alongside it. CXXC5 was characterized as the mediator of PGD2-induced hair loss, with that hair loss reversed by *Cxxc5* knockout or by PTD-DBM, a peptide that activates Wnt/beta-catenin by interfering with CXXC5's Dvl-binding function — and CXXC5 also mediates DHT-induced hair loss via PGD2, with DHT-induced loss alleviated by inhibiting both GSK-3beta and CXXC5 (Ryu 2023). If that chain holds, this is a lever on androgenetic hair loss that does not require touching androgens.

    Mechanistic
  • Wound repair, with the specific proteins named. In human keratinocytes and dermal fibroblasts KY-19382 increased migration with raised beta-catenin, phalloidin, Keratin 14, PCNA, Collagen I and alpha-SMA, without significant cytotoxicity; in a murine cutaneous wound model it raised Collagen I, Keratin 14, PCNA and stem cell markers and accelerated re-epithelialization and neo-epidermis formation with collagen deposition at an early stage (Yoon 2023). Note that this is injured skin, where the barrier that would otherwise govern delivery is absent.

    Experimental, animal or cell
  • It works where Wnt is suppressed, which is the cleanest test of a restorative mechanism. In *db/db* mice and in high-fat-diet plus streptozotocin diabetic mice, hair regrowth and WIHN were reduced through suppression of Wnt/beta-catenin; KY-19382 restored both (Ryu 2022). A brake-release mechanism should do most for tissue whose brake is most engaged, and that is what was observed.

    Experimental, animal or cell
  • The finding that complicates the proliferation worry, from the developers' own hands. (Lee 2025) opens by conceding that Wnt is hard to drug because of *its concerning role in cancer*, then reports that KY19382 and KY19334 INHIBITED Wnt/beta-catenin signaling in human cutaneous squamous cell carcinoma cells, with suppressed CDK1 expression, and that the two molecules attenuated two-stage mouse skin carcinogenesis. The direction of effect on Wnt inverted in a tumor context. That is the opposite of what a naive reading of 'Wnt activator' predicts, it is the most important safety datum this compound has, and it is the developer's own work rather than an independent replication.

    Experimental, animal or cell

Sources

KY-19382 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Skin cancer, a suspicious mole or a precancerous lesion, because Wnt and beta-catenin activation drives proliferation.
  • Family history of colon polyposis or colorectal cancer, where Wnt signaling is already central.
  • Broken or infected scalp skin.
  • Pregnancy or breastfeeding, since Wnt signaling drives fetal tissue patterning.

What’s expected

  • Hair follicle and wound-healing signaling is released by blocking the CXXC5 brake.
  • Local pinkness or tingling.
  • Effects shown in mouse and human-cell models, not human trials.

Watch for

  • A mole or patch that changes after weeks of use.
  • Persistent scaling or a nodule on the treated area.
  • Redness that spreads beyond the treated patch.

Labs that tell you it’s working

  • Total DHT & Free DHT: the DHT-CXXC5 pathway is the hair-loss mechanism being targeted.
  • Comprehensive Metabolic Panel: baseline only, as topical absorption of a small molecule is expected to be low.

Disrupts the CXXC5-Dishevelled interaction so Wnt and beta-catenin signaling is released; the predicted harm is proliferation, not toxicity. PMID 33751552 PMID 36831222 PMID 37524876

Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON

KY-19382 FAQ4 common questions

Is KY-19382 approved for human use?
No. KY-19382 is a research compound. No completed randomized human trial has given it yet.
What is KY-19382 researched for?
A Wnt/beta-catenin pathway activator acting through blockade of the CXXC5–Dishevelled interaction, studied for hair regrowth and hair follicle neogenesis, cutaneous wound healing, and dermal matrix and collagen…
Which labs show whether it's doing anything?
Total DHT & Free DHT; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for KY-19382: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what KY-19382 is. Skool covers how it is run.

Free on this page

What KY-19382 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What KY-19382 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool